1
|
Coughlan A, Klijn SL, Xiao H, White B, Franco-Villalobos C, Sichevaya A, Hnoosh A, Miteva D, Yucel A. HSR24-132: Value of Early Transfusion Burden Reduction in Lower-Risk Myelodysplastic Syndromes (LR-MDS). J Natl Compr Canc Netw 2024; 22:HSR24-132. [PMID: 38579810 DOI: 10.6004/jnccn.2023.7266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2024]
Affiliation(s)
| | | | - Hong Xiao
- 2Bristol Myers Squibb, Princeton, NJ
| | | | | | | | | | - Dimana Miteva
- 7Celgene International Sarl, a Bristol Myers Squibb Company, Boudry, Switzerland
| | | |
Collapse
|
2
|
Karver TS, Pascual-Bernaldez M, Berni A, Hnoosh A, Castagna A, Messiaen P, Puerto MJG, Bloch M, Adachi E, Sinclair G, Felizarta F, Angel JB, Sutton K, Sutherland-Phillips D, D'Amico R, Kerrigan D. Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical Trial. AIDS Patient Care STDS 2023; 37:53-59. [PMID: 36626155 DOI: 10.1089/apc.2022.0168] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
Cabotegravir and rilpivirine long-acting (LA) antiretroviral therapy (ART) demonstrated similar safety and efficacy in maintaining viral suppression among participants switching from daily oral to LA ART in the Extension Phase of the FLAIR trial. The Phase IIIb SOLAR study comparing efficacy and safety of daily oral versus LA ART every 2 months allowed participants and health care providers (HCPs) to choose an oral lead-in (OLI) before LA initiation or proceed by immediately starting with injections (SWI). We conducted an online survey among SOLAR HCPs (n = 110) in 13 countries to assess reasons for choosing OLI versus SWI. Logistic regression was used to identify factors influencing this decision. Thirty-two percent of HCPs reported a future preference to use OLI, whereas 54% reported a future preference for SWI. HCPs had greater odds of reporting future intentions for SWI if they were from Continental Europe versus North America [adjusted odds ratio (aOR): 3.83, p < 0.05], from sites with a greater number of participants who initiated LA ART without OLI (aOR: 1.56, p < 0.01), and those who reported comfort with the medication safety profile (aOR: 6.39, p < 0.01). HCPs who participated in LA ART trials before SOLAR had decreased odds of reporting a preference for SWI compared to those with no prior LA ART trial experience (aOR: 0.11; p < 0.01). Results indicated higher intentions to SWI over OLI among HCPs initiating participants on LA ART. A major factor associated with SWI was provider comfort with safety data, reinforcing the role of continued training regarding an SWI approach.
Collapse
Affiliation(s)
- Tahilin Sanchez Karver
- Department of Prevention and Community Health, The George Washington University Milken Institute School of Public Health, Washington, District of Columbia, USA.,Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
| | | | | | - Ahmed Hnoosh
- Formerly with ViiV Healthcare, Brentford, United Kingdom
| | | | - Peter Messiaen
- Department of Infectious Diseases and Immunity, Jessa Hospital, Hasselt, Belgium.,Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium
| | | | - Mark Bloch
- Holdsworth House Medical Practice, and University of New South Wales, Sydney, Australia.,Department of Medicine, University of New South Wales, Sydney, Australia
| | - Eisuke Adachi
- Department of Infectious Diseases and Applied Immunology, Hospital of the Institute of Medical Science, University of Tokyo, Tokyo, Japan
| | | | | | | | - Kenneth Sutton
- ViiV Healthcare, Research Triangle Park, North Carolina, USA
| | | | - Ronald D'Amico
- ViiV Healthcare, Research Triangle Park, North Carolina, USA
| | - Deanna Kerrigan
- Department of Prevention and Community Health, The George Washington University Milken Institute School of Public Health, Washington, District of Columbia, USA
| |
Collapse
|
3
|
Hnoosh A, Harty GT, Sullivan L, Byrne B, von Honhorst P. Cost Effectiveness Of Cetuximab In First Line Treatment Of Ras Wild-Type Metastatic Colorectal Cancer In The Uk: A Summary Of Economic Analyses Submitted To The National Institute For Health And Care Excellence (Nice). Value in Health 2015. [PMID: 0 DOI: 10.1016/j.jval.2015.09.1182] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/07/2023]
|
4
|
Jarrett J, Ovcinnikova O, Hnoosh A, Harty G, Byrne B, von Hohnhorst P. Cost Effectiveness of Cetuximab in 1st-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer in Scotland: A Summary of the Submission to the Scottish Medicines Consortium. Value Health 2014; 17:A638. [PMID: 27202280 DOI: 10.1016/j.jval.2014.08.2296] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
| | | | | | | | - B Byrne
- Merck Serono Ltd., FELTHAM, UK
| | | |
Collapse
|
5
|
Jarrett J, Weijers L, Hnoosh A, Harty G, von Hohnhorst P. A Systematic Literature Review to Identify Trials in First-Line Ras Wild-Type (WT) Metastatic Colorectal Cancer (MCRC) Patients. Value Health 2014; 17:A617. [PMID: 27202163 DOI: 10.1016/j.jval.2014.08.2174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
| | - L Weijers
- Mapi - HEOR & Strategic Market Access, Houten, The Netherlands
| | | | | | | |
Collapse
|